ADMA Biologics (ADMA) vs Alvotech (ALVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ADMA Biologics (ADMA) has outperformed Alvotech (ALVO) over the past year, losing 29.3% versus a loss of 34.7%. ADMA Biologics is the larger company by market cap ($2.31 billion vs $2.02 billion), about 1.1 times the size, while Alvotech is growing revenue faster (+19.7% vs +19.6%). On valuation, ADMA Biologics trades at a lower forward P/E (11.0x vs 24.8x for Alvotech).
ADMA Biologics converts more of its revenue into profit, with a net margin of 28.8% versus 4.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | ALVO |
|---|---|---|
| Share price | $10.33 | $5.67 |
| Market cap | $2.31B | $2.02B |
| 1-day change | +1.87% | -3.08% |
| YTD return | -43.37% | +10.53% |
| 1-year return | -29.34% | -34.68% |
| 5-year return | +839.09% | — |
| P/E ratio (TTM) | 14.76 | — |
| Forward P/E | 10.95 | 24.83 |
| EPS (TTM) | $0.70 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $510.17M | $586.32M |
| Revenue growth (YoY) | +19.63% | +19.74% |
| Net income (latest FY) | $146.93M | $27.92M |
| Gross margin | 57.39% | 59.82% |
| Operating margin | 37.53% | 13.34% |
| Net margin | 28.80% | 4.76% |
| 52-week high | $20.46 | $9.05 |
| 52-week low | $7.21 | $2.94 |
| Distance from 52-week high | -49.51% | -37.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +64.57% | +19.93% |
| Average volume | 2.63M | 1.05M |
| Shares outstanding | 223.98M | 356.82M |
| Employees | 640 | 1,279 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADMA Biologics is more profitable, keeping 28.8 cents of every revenue dollar as net income versus 4.8 cents for Alvotech.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Alvotech
ALVO stock →Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees
ADMA vs ALVO FAQ
Which is bigger, ADMA Biologics or Alvotech?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.31B compared with $2.02B for Alvotech (ALVO).
Which stock has performed better over the past year, ADMA or ALVO?
ADMA returned -29.34% over the past 12 months, compared with -34.68% for ALVO (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Alvotech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.